phase II clinical study
Lion TCR to Begin Phase Ib/II Trial of Autologous Liver Cancer T-Cell Receptor Therapy
The FDA has cleared an investigational new drug application for Lion's LioCyx-M004 for advanced hepatitis B virus-related hepatocellular carcinoma patients.
Rain Therapeutics' Milademetan Shows Clinical Activity in MDM2-Amplified Intimal Sarcoma
Data presented at the ESMO Congress provided proof of concept for MDM2 inhibition in patients with these ultra-rare sarcomas and limited treatment options.
Salarius, Fox Chase Cancer Center to Explore New Indications, Biomarkers for Seclidemstat
The drugmaker is partnering with the Cancer Epigenetics Institute to identify new therapeutic opportunities for the drug in LSD1-driven solid tumors.
Erasca Begins Phase Ib/II Master Protocol Trial of ERAS-007 in Gastrointestinal Cancers
The company will initially study the ERK1/2 inhibitor in combination with other therapies in biomarker-defined advanced colorectal cancers.
Verastem Oncology, Amgen Partner to Study RAF/MEK Inhibitor With Lumakras in NSCLC
Researchers will track the regimen's activity in NSCLC patients with KRAS G12C mutations who haven't received similar therapies and those who have become resistant to them.